358348-70-6

Upstream product

• 3376-59-8 2,3-dihydroxypropyl benzoate 
• 71-30-7 Cytosine 
• 143919-90-8 2-benzoyloxymethyl-5-acethoxy-1,3-oxathiolane 
• 98760-27-1 4-benzoyloxymethyl-2,2-dimethyl-[1,3]dioxolane 
• 138760-43-7 2-Benzyloxymethyl-5-ethoxy-1,3-oxathiolane 
• 56653-26-0 4-Pyrimidinamine, [(trimethylsilyl)oxy]- 
• 64904-47-8 2-benzoyloxyacetaldehyde 
• 18037-10-0 2,4-O,N-bis(trimethylsilyl)cytosine 
• 144897-15-4 2-benzoyloxymethyl-5-<2-methoxyethyloxy>-1,3-oxathiolane 

Downstream Products

• 134678-17-4 lamivudine 
• 136831-90-8 cis-2-<<(tert-butyldiphenylsilyl)oxy>methyl>-5-(cytosin-1'-yl)-1,3-oxathiolane 
• 131086-21-0 (+/-)-cis-N-<2-(hydroxymethyl)-1,3-oxathiolan-5-yl>cytosine 
• 1091585-30-6 trans-2-benzoyloxymethyl-5-(N'4-acetylcytosin-1'-yl)-1,3-oxathiolane 
• 1091585-30-6 cis-2-benzoyloxymethyl-5-(N'4-acetylcytosin-1'-yl)-1,3-oxathiolane 

Relevant academic research and scientific papers

PROCESS FOR THE MANUFACTURE OF CIS(-)-LAMIVUDINE

An improved process for the manufacture of Lamivudine. The process involves: (a) resolution of racemic lamivudine (intermediate of formula IX) to cis (±) lamivudine of formula (XII) by forming a crystalline salt and separating the product from an organic solvent by fractional crystallization; (b) resolution of cis (±) lamivudine to cis (?) isomer involving formation of S-Binol adduct of formula XIV.

2-Substituted-4-substituted-1,3-dioxolanes and use thereof

Nucleoside analogues containing a 1,3-dioxolane structure are suitable antiviral agents, particulary for the treatment of the HIV infections in mammals, especially humans. Examples of the nucleoside analogues include: cis-2-acetoxymethyl-4-(thymin-1′-yl)-1,3,-dioxolane, cis-2-hydroxymethyl-4-(thymin-1′-yl)-1,3-dioxolane, cis-2-benzoyloxymethyl-4-(cytosin-1′-yl)-1,3-dioxolane, and cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-dioxolane. These compounds can be in the form of their racemates or their separate enantiomers.